New treatment for generalized anxiety disorder
Part of Mental health clinical trials.
This trial tests a new medication called RE104 for people with generalized anxiety disorder (GAD). The goal is to see if it helps reduce anxiety symptoms safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with generalized anxiety disorder (GAD).
- You are not pregnant or planning to become pregnant (if female), or you are not planning to get a partner pregnant (if male).
- You are willing to follow the study rules and come to appointments.
- You do not have a high risk of suicide.
- You do not have bipolar disorder, schizophrenia, or other psychotic disorders (or a family history of these).
- You do not have other serious medical conditions that would make the study unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational oral medication (ITI-1284) for people with moderate to severe generalized anxiety disorder (GAD) who haven't found enough relief from at least two standard medications. The goal is to see if this new drug helps reduce anxiety symptoms.
This trial tests an investigational medication to see if it can reduce anxiety symptoms in adults with generalized anxiety disorder. Participants will receive the study drug and be monitored for safety and effectiveness.
This study tests a new medicine (SEP-363856) for adults with generalized anxiety disorder to see if it reduces anxiety symptoms and is safe. It may help if other treatments haven't worked well.
This trial tests a new medication, JNJ-99245354 (also called ITI-1284), added to your current anxiety treatment to see if it helps reduce anxiety symptoms. You may be eligible if you've already tried at least one FDA-approved treatment for generalized anxiety disorder without enough improvement.
This trial tests a new medicine called SYT-510 for adults with generalized anxiety disorder who are not currently taking medication. It aims to see if the drug reduces anxiety and is safe.
This study is for adults who already completed an earlier phase 3 trial of this anxiety medication and are continuing it. It tests how safe and tolerable the medication is when used for a longer period for generalized anxiety disorder.
Hear when a new Generalized Anxiety Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.